Ace Therapeutics employs advanced analytical technologies and animal models to assist customers in identifying and validating biomarkers for use in the diagnosis of psychiatric disorders. Our comprehensive solutions provide clients in the pharmaceutical industry and research organizations with reliable markers for psychiatric disorders diagnosis. We utilize our advanced technology platform and dedicated research team to ensure the high-quality and efficiency of our services, and we are committed to bringing revolutionary diagnostic tools to the psychiatric disorders field.

Introduction of Diagnostic Biomarkers for Psychiatric Disorders

Diagnostic biomarkers are a category of biomarkers that are used to detect or confirm the presence of a disease or medical condition. Such biomarkers facilitate the accurate diagnosis of psychiatric disorders and enhance the effectiveness of treatment responses, while also enabling the re-classification of diseases. Furthermore, diagnostic biomarkers can play a pivotal role as prognostic or predictive treatment outcome biomarkers. For instance, the concentrations of Aβ42 and total tau (T-tau) in the cerebrospinal fluid of patients with dementia can be utilized as diagnostic biomarkers for Alzheimer's disease.

Our Research Areas

• Blood biomarker development
• Cerebrospinal fluid biomarker development
• Genetic biomarker development
• Imaging biomarker development

Our Advanced Technologies and Research Methods

Ace Therapeutics is committed to utilizing a broad range of advanced technologies to assist our clients in exploring and identifying key diagnostic biomarkers for psychiatric disorders in a cost-effective, simple, and easy-to-detect manner. Our methods and advanced technologies include, but are not limited to, the following:

• Multi-omics technologies: Multi-omics technologies such as genomics, transcriptomics, proteomics, metabolomics and epigenetics are used to discover and validate biomarkers to detect multidimensional stages of disease.
• High-throughput screening: Using high-throughput sequencing, mass spectrometry analysis and other technologies to obtain comprehensive bioinformatic data from the levels of genes, transcription, proteins and metabolism.
• Bioinformatics analysis: Import multi-omics data into the bioinformatics platform, use advanced algorithms and statistical models for data cleaning, pre-processing, feature selection and association analysis. Look for biomarkers that are significantly altered in patients with psychiatric disorders, such as specific gene variants, abnormally expressed mRNAs, proteins, or metabolites.

Processes for Biomarker Development Services for Psychiatric Diagnosis

• Requirements analysis and project planning: Develop a personalized project plan based on the client's target disease, intended application, sample type and other requirements.
• Sample collection and pre-processing: Samples may include blood, cerebrospinal fluid, tissue slices, and so on. Our experienced project experts will perform the necessary pre-processing to ensure the quality of the samples.
• Biomarker discovery: We utilize multi-combinatorial technologies to help our clients discover potential biomarkers associated with mental illnesses and analyze the data to identify differentially expressed molecules through bioinformatics methods.
• Biomarker validation: We conduct functional studies on the discovered potential diagnostic biomarkers through in vitro cellular assays and animal models to validate their mechanisms of action in disease onset and progression.
• Data analysis and reporting: We provide detailed sub-license reports based on the results of the tests.

Ace Therapeutics offers biomarker development services for psychiatric diagnostics, providing clients with an efficient pathway to accurately identify and validate disease-related markers from complex biological data. Please contact us for more details and we will be happy to assist you.